Table 1.
Summary of patient characteristics across WHO 2017 WBC count–based subtypes, MDS- and MP-CMML
| Variable | MDS-CMML | MP-CMML | P* |
|---|---|---|---|
| Patients, N (%) | 306 (48.6) | 323 (51.4) | |
| Age, median (range), y | 69.9 (31.2-91.1) | 69.9 (24.8-87.6) | .9559 |
| Age group, n (%), y | |||
| <60 | 61 (19.9) | 55 (17.0) | .4987 |
| 60-69 | 152 (49.7) | 158 (48.9) | |
| ≥70 | 93 (30.4) | 110 (34.1) | |
| Sex, n (%) | |||
| Female | 93 (30.4) | 106 (32.8) | .5133 |
| Male | 213 (69.6) | 217 (67.2) | |
| WHO-2017, n (%) | |||
| CMML-0 | 122 (39.9) | 92 (28.5) | .0052 |
| CMML-1 | 101 (33.0) | 113 (35.0) | |
| CMML-2 | 83 (27.1) | 118 (36.5) | |
| WHO-2008, n (%) | |||
| CMML-1 | 223 (72.9) | 205 (63.5) | .0114 |
| CMML-2 | 83 (27.1) | 118 (36.5) | |
| PB parameters | |||
| WBC count, median (range), ×109/L | 7.3 (0.8-12.9) | 28.7 (13.0-223.1) | <.0001 |
| Hemoglobin concentration, median (range), g/dL | 10.6 (5.9-16.0) | 10.2 (5.1-16.4) | .0905† |
| Platelet count, median (range), ×109/L | 88.5 (2.0-1554) | 94.0 (5.0-912.0) | .2705 |
| Immature myeloid cells,‡ median (minimum-maximum) | 1.0 (0.0-34.0) | 8.0 (0.0-50.0) | <.0001 |
| LDH, median (range), IU/L | 537.0 (191-3400) | 749.0 (142-11060) | <.0001 |
| BM blast percentage, median (range) | 5.5 (0.0-19.0) | 6.0 (0.0-19.0) | .7885 |
| MDAPS group, n (%) | |||
| High | 47 (15.4) | 57 (17.6) | <.0001 |
| Intermediate-2 | 98 (32.0) | 186 (57.6) | |
| Intermediate-1 | 110 (35.9) | 66 (20.4) | |
| Low | 51 (16.7) | 14 (4.3) | |
| CPSS group, n (%) | |||
| HIGH | 16 (5.2) | 49 (15.2) | <.0001 |
| INT-2 | 85 (27.8) | 178 (55.1) | |
| INT-1 | 90 (29.4) | 96 (29.7) | |
| Low | 115 (37.6) | 0 (0) | |
| CPSS cytogenetic risk groups, n (%) | |||
| High | 58 (19.0) | 50 (15.5) | .0704 |
| Intermediate | 36 (11.8) | 58 (18.0) | |
| Low | 212 (69.3) | 215 (66.6) | |
| Tang cytogenetic risk groups, n (%) | |||
| High | 36 (11.8) | 36 (11.1) | .5856 |
| Intermediate | 58 (19.0) | 72 (22.3) | |
| Low | 212 (69.3) | 215 (66.6) | |
| Mutations, present, n (%) | |||
| TET2 | 40 (41.7) | 35 (38.9) | .6995 |
| ASXL1 | 26 (37.7) | 36 (50.7) | .1209 |
| RAS | 42 (17.4) | 88 (36.5) | <.0001 |
| TP53 | 5 (5.2) | 5 (5.6) | .9164 |
| RUNX1 | 15 (21.7) | 13 (18.3) | .6121 |
| Follow-up duration, median (range), mo | 23.6 (0.0-191.9) | 17.2 (0.0-147.0) | <.0001 |
| Death, n (%) | 183 (59.8) | 249 (77.1) | <.0001 |
| Survival time, median (95% CI), mo | 33.8 (28.8-40.0) | 21.1 (18.4-24.5) | <.0001 |
| Duration to AML transformation, median (range), mo | 22.0 (0.0-185.2) | 15.2 (0.0-138.9) | <.0001 |
| AML, n (%) | 49 (16.0) | 61 (18.9) | .3432 |
LDH, lactate dehydrogenase.
*
Kruskal-Wallis test and Wilcoxon rank-sum test for continuous factors and χ2 test for categorical factors as appropriate.
†
Full comparison conducted using treatment-naïve group (n = 499) showed comparable results with the following exception: P significant (.0251) in treatment-naïve group.
‡
Sum of promyelocytes, myelocytes, and metamyelocytes in PB.